Mizuho analyst Uy Ear lowered the firm’s price target on Selecta Biosciences to $5 from $8 and keeps a Buy rating on the shares post the Q4 results. The company continues to make progress on its pipeline, with SEL-212 Phase 3 data readout on track for later this month, As previously reported,
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SELB:
- Selecta Biosciences sees cash runway into mid-2024
- Selecta Biosciences reports Q4 EPS 4c, consensus (7c)
- Selecta Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Selecta Biosciences to Participate at the SVB Securities Global Biopharma Conference
- Selecta Biosciences management to meet virtually with Cantor Fitzgerald